These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 16705315)

  • 1. A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.
    Newton R; Carpenter L; Casabonne D; Beral V; Babiker A; Darbyshire J; Weller I; Weiss R; Kwan A; Bourboulia D; Munoz F; Lagos D; Boshoff C
    Br J Cancer; 2006 May; 94(10):1504-9. PubMed ID: 16705315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
    Callahan J; Pai S; Cotter M; Robertson ES
    Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroreactivity to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen in AIDS-associated Kaposi's sarcoma patients depends on CD4+ T-cell count.
    de Souza VA; Pierrotti LC; Sumita LM; Freire WS; Segurado AA; Pannuti CS
    J Med Virol; 2007 Oct; 79(10):1562-8. PubMed ID: 17705173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of humoral immune responses to Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus using a viral proteome microarray.
    Zheng D; Wan J; Cho YG; Wang L; Chiou CJ; Pai S; Woodard C; Zhu J; Liao G; Martinez-Maza O; Qian J; Zhu H; Hayward GS; Ambinder RF; Hayward SD
    J Infect Dis; 2011 Dec; 204(11):1683-91. PubMed ID: 21990424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Kaposi's sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi's sarcoma: a nested case-control study.
    Wakeham K; Johnston WT; Nalwoga A; Webb EL; Mayanja BN; Miley W; Elliott AM; Whitby D; Newton R
    Int J Cancer; 2015 Jun; 136(12):2822-30. PubMed ID: 25395177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutual detection of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in blood and saliva of Cameroonians with and without Kaposi's sarcoma.
    Labo N; Marshall V; Miley W; Davis E; McCann B; Stolka KB; Ndom P; Hemingway-Foday JJ; Abassora M; Newton R; Smith JS; Whitby D
    Int J Cancer; 2019 Nov; 145(9):2468-2477. PubMed ID: 31265124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma.
    Gao SJ; Kingsley L; Hoover DR; Spira TJ; Rinaldo CR; Saah A; Phair J; Detels R; Parry P; Chang Y; Moore PS
    N Engl J Med; 1996 Jul; 335(4):233-41. PubMed ID: 8657239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.
    Engels EA; Biggar RJ; Marshall VA; Walters MA; Gamache CJ; Whitby D; Goedert JJ
    AIDS; 2003 Aug; 17(12):1847-51. PubMed ID: 12891072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma.
    Renwick N; Halaby T; Weverling GJ; Dukers NH; Simpson GR; Coutinho RA; Lange JM; Schulz TF; Goudsmit J
    AIDS; 1998 Dec; 12(18):2481-8. PubMed ID: 9875587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of human sera reactivities in immunoblots with recombinant human herpesvirus (HHV)-8 proteins associated with the latent (ORF73) and lytic (ORFs 65, K8.1A, and K8.1B) replicative cycles and in immunofluorescence assays with HHV-8-infected BCBL-1 cells.
    Zhu L; Wang R; Sweat A; Goldstein E; Horvat R; Chandran B
    Virology; 1999 Apr; 256(2):381-92. PubMed ID: 10191203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon.
    Stolka K; Ndom P; Hemingway-Foday J; Iriondo-Perez J; Miley W; Labo N; Stella J; Abassora M; Woelk G; Ryder R; Whitby D; Smith JS
    Cancer Epidemiol; 2014 Apr; 38(2):137-43. PubMed ID: 24631417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for Kaposi's sarcoma: a case-control study of HIV-seronegative people in Uganda.
    Ziegler J; Newton R; Bourboulia D; Casabonne D; Beral V; Mbidde E; Carpenter L; Reeves G; Parkin DM; Wabinga H; Mbulaiteye S; Jaffe H; Weiss R; Boshoff C;
    Int J Cancer; 2003 Jan; 103(2):233-40. PubMed ID: 12455038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kaposi's sarcoma-associated herpesvirus seroprevalence in selected german patients: evaluation by different test systems.
    Preiser W; Szép NI; Lang D; Doerr HW; Rabenau HF
    Med Microbiol Immunol; 2001 Dec; 190(3):121-7. PubMed ID: 11827200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy.
    Guadalupe M; Pollock BH; Westbrook S; Redding S; Bullock D; Anstead G; Agan BK; Marconi VC; Barbieri S; Sankar V; Rebeles J; Flahive Y; Schoolfield J; Wang L; Lei X; Dow D; Yeh CK; Dang H; Infante AJ; Gao SJ
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):83-90. PubMed ID: 21084997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.
    Miller G; Rigsby MO; Heston L; Grogan E; Sun R; Metroka C; Levy JA; Gao SJ; Chang Y; Moore P
    N Engl J Med; 1996 May; 334(20):1292-7. PubMed ID: 8609946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Kaposi's sarcoma-associated herpesvirus in HIV-1-infected US persons in the era of combination antiretroviral therapy.
    Labo N; Miley W; Benson CA; Campbell TB; Whitby D
    AIDS; 2015 Jun; 29(10):1217-25. PubMed ID: 26035321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of Kaposi's Sarcoma-Associated Herpesvirus Latency Using CRISPR-Cas9 To Edit the Latency-Associated Nuclear Antigen Gene.
    Tso FY; West JT; Wood C
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection with Kaposi's sarcoma-associated herpesvirus (KSHV) and human immunodeficiency virus (HIV) in relation to the risk and clinical presentation of Kaposi's sarcoma in Uganda.
    Newton R; Ziegler J; Bourboulia D; Casabonne D; Beral V; Mbidde E; Carpenter L; Parkin DM; Wabinga H; Mbulaiteye S; Jaffe H; Weiss R; Boshoff C
    Br J Cancer; 2003 Aug; 89(3):502-4. PubMed ID: 12888820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) in Kaposi's sarcoma, malignant lymphoma, and other diseases.
    Knowles DM; Cesarman E
    Ann Oncol; 1997; 8 Suppl 2():123-9. PubMed ID: 9209655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.